Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.
Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.